MEK and SHP2 inhibition similarly shrank tumors in our preclinical studies, suggesting that SHP2 inhibition might act as an alternative for MEK inhibition in neurofibroma therapy. The gene discussed is PTPN11; the disease is plexiform neurofibroma.